Jose Alberto Lopez-Dominguez

Jose Alberto Lopez-Dominguez

Auto-generated profile, based on publicly available information

Jose Alberto Lopez-Dominguez

Buck Institute for Research on Aging, Novato, CA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Cell Metabolism
Verified
Journal Article
Closed access
MRMegan N. Roberts
Megan N. Roberts
MWMarita A. Wallace
Marita A. Wallace
ATAlexey A. Tomilov
Alexey A. Tomilov
ZZZeyu Zhou
Zeyu Zhou
GMGeorge R. Marcotte
George R. Marcotte
JLJose Alberto Lopez-Dominguez
Jose Alberto Lopez-Dominguez

16 November 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
ACAnthony J. Covarrubias
Anthony J. Covarrubias
AKAbhijit Kale
Abhijit Kale
Rosalba PerroneRosalba Perrone
Rosalba Perrone
JLJose Alberto Lopez-Dominguez
Jose Alberto Lopez-Dominguez
APAngela Oliveira Pisco
Angela Oliveira Pisco
EVEric Verdin
Eric Verdin

27 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
IMInes Marin
Ines Marin
OBOlga Boix
Olga Boix
AGAndrea Garcia-Garijo
Andrea Garcia-Garijo
ISIsabelle Sirois
Isabelle Sirois
ACAdrià Caballe
Adrià Caballe
MSManuel Serrano
Manuel Serrano
Cellular senescence is a stress response that activates innate immune cells, but little is known about its interplay with the adaptive immune system. Here, we show that senescent cells combine several features that render them highly efficient in activating dendritic cells (DC) and antigen-specific CD8 T cells. This includes the release of alarmins, activation of IFN signaling, enhanced MHC class I machinery, and presentation of senescence-associated self-peptides that can activate CD8 T cells. In the context of cancer, immunization with senescent cancer cells elicits strong antitumor protection mediated by DCs and CD8 T cells. Interestingly, this protection is superior to immunization with cancer cells undergoing immunogenic cell death. Finally, the induction of senescence in human primary cancer cells also augments their ability to activate autologous antigen-specific tumor-infiltrating CD8 lymphocytes. Our study indicates that senescent cancer cells can be exploited to develop efficient and protective CD8-dependent antitumor immune responses. Significance: Our study shows that senescent cells are endowed with a high immunogenic potential—superior to the gold standard of immunogenic cell death. We harness these properties of senescent cells to trigger efficient and protective CD8-dependent antitumor immune responses. See related article by Chen et al., p. 432. This article is highlighted in the In This Issue feature, p. 247

1 September 2019 in Cell Reports
Verified
Journal Article
Open access
CWChristopher D. Wiley
Christopher D. Wiley
SLSu Liu
Su Liu
CLChandani Limbad
Chandani Limbad
AZAnna M. Zawadzka
Anna M. Zawadzka
JBJennifer Beck
Jennifer Beck
PKPankaj Kapahi
Pankaj Kapahi
Cellular senescence irreversibly arrests cell proliferation, accompanied by a multi-component senescence-associated secretory phenotype (SASP) that participates in several age-related diseases. Using stable isotope labeling with amino acids (SILACs) and cultured cells, we identify 343 SASP proteins that senescent human fibroblasts secrete at 2-fold or higher levels compared with quiescent cell counterparts. Bioinformatic analysis reveals that 44 of these proteins participate in hemostasis, a process not previously linked with cellular senescence. We validated the expression of some of these SASP factors in cultured cells and in vivo. Mice treated with the chemotherapeutic agent doxorubicin, which induces widespread cellular senescence in vivo, show increased blood clotting. Conversely, selective removal of senescent cells using transgenic p16-3MR mice showed that clearing senescent cells attenuates the increased clotting caused by doxorubicin. Our study provides an in-depth, unbiased analysis of the SASP and unveils a function for cellular senescence in hemostasis.

5 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CWChristopher D. Wiley
Christopher D. Wiley
NSNicholas Schaum
Nicholas Schaum
FAFatouma Alimirah
Fatouma Alimirah
JLJose Alberto Lopez-Dominguez
Jose Alberto Lopez-Dominguez
AOArturo V. Orjalo
Arturo V. Orjalo
JCJudith Campisi
Judith Campisi
Processes that have been linked to aging and cancer include an inflammatory milieu driven by senescent cells. Senescent cells lose the ability to divide, essentially irreversibly, and secrete numerous proteases, cytokines and growth factors, termed the senescence-associated secretory phenotype (SASP). Senescent cells that lack p53 tumor suppressor function show an exaggerated SASP, suggesting the SASP is negatively controlled by p53. Here, we show that increased p53 activity caused by small molecule inhibitors of MDM2, which promotes p53 degradation, reduces inflammatory cytokine production by senescent cells. Upon treatment with the MDM2 inhibitors nutlin-3a or MI-63, human cells acquired a senescence-like growth arrest, but the arrest was reversible. Importantly, the inhibitors reduced expression of the signature SASP factors IL-6 and IL-1α by cells made senescent by genotoxic stimuli, and suppressed the ability of senescent fibroblasts to stimulate breast cancer cell aggressiveness. Our findings suggest that MDM2 inhibitors could reduce cancer progression in part by reducing the pro-inflammatory environment created by senescent cells.

24 January 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SCSelim Chaib
Selim Chaib
JLJosé Alberto López-Domínguez
José Alberto López-Domínguez
MLMarta Lalinde-Gutiérrez
Marta Lalinde-Gutiérrez
NPNeus Prats
Neus Prats
IMInes Marin
Ines Marin
MSManuel Serrano
Manuel Serrano
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence.